140 - When Cutting Edge Approaches in Adult and pediatric transplantation Go Viral…

Speaker(s)

• 

  Catherine Bollard, MD, FRACP, FRCPA

  Bosworth Chair for Cancer Biology Professor of Pediatrics and of Microbiology, Immunology and Tropical Medicine Director,, Center for Cancer and Immunology Research Director, Program for Cell Enhancement and Technologies for Immunotherapy
  Children's National Hospital and The George Washington University, Maryland

  Disclosure: Cabaletta Bio : Board Member (Status: Ongoing), Other Financial or Material Support (Status: Ongoing), Stock options (Status: Ongoing); Catamaran Bio : Co-Founder / SAB / Stock Options (Status: Ongoing), Other Financial or Material Support (Status: Ongoing); Mana Therapeutics : Co-founder / SAB / Stock Options (Status: Ongoing), Other Financial or Material Support (Status: Ongoing); Neximmune : Other Financial or Material Support (Status: Ongoing), Stock options (Status: Ongoing); Repertoire Immune Medicines (formerly Torque Therapeutics) : Other Financial or Material Support (Status: Ongoing), Stock options (Status: Ongoing)
• 

  Paul Carpenter, MB. BS., BSc. (Med)

  Full Member
  Clinical Research Division
  Fred Hutchinson Cancer Research Center; University of Washington
  Seattle, Washington

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• 

  Brian Fisher, DO, MPH, MSCE

  Associate Professor of Pediatrics and Epidemiology
  Division of Infectious Diseases; Center for Pediatric Clinical Effectiveness
  Children's Hospital of Philadelphia; Perelman School of Medicine, University of Pennsylvania
  Philadelphia, Pennsylvania

  Disclosure: Astellas () : Advisor or Review Panel member; Merck () : Grant/Research Support; Pfizer () : Grant/Research Support

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit

No CPE Credits

Learning Objectives:

• explain hard to treat viruses in HCT
• discuss vaccination schedules for transplant patients
• discuss the possibility of virus-specific T-cell therapy

Presentations:

• 1:15pm – 3:00pm EDT

  Hard to Treat DNA Viruses in HCT – Adenovirus and EBV
  Brian T. Fisher, DO, MPH, MSCE – Children's Hospital of Philadelphia; Perelman School of Medicine, University of Pennsylvania
• 1:15pm – 3:00pm EDT

  Rethinking Vaccination Schedules in Transplantation in an Era with Re-emergence of Vaccine Preventable Diseases
  Paul A. Carpenter, MB. BS., BSc. (Med) – Fred Hutchinson Cancer Research Center; University of Washington
• 1:15pm – 3:00pm EDT

  When Will Virus Specific T Cell Therapy Be Ready for Prime Time?
  Catherine M. Bollard, MD, FRACP, FRCPA – Children's National Hospital and The George Washington University